SBI Securities’s PharmaCyte Biotech PMCB Stock Holding History

SBI Securities’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Buy	6 +3	+100%	+$2	﹤0.01%	3986
2026 Q1	$2	Buy	+3	New	+$2	﹤0.01%	3966

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SBI Securities's PMCB Position: Q2 2026 in Review

SBI Securities increased its PharmaCyte Biotech (PMCB) stake by 100% in Q2 2026, buying an estimated $2 and bringing the position to 6 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #3986.

SBI Securities first reported a position in PMCB in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

SBI Securities held 6 shares of PharmaCyte Biotech worth $5 as of Q2 2026.
SBI Securities bought 3 PharmaCyte Biotech shares in Q2 2026, an estimated $2.
PharmaCyte Biotech made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3986 holding.
SBI Securities first reported a position in PharmaCyte Biotech in Q1 2026 and has held it in 2 quarters since.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.